Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

BACKGROUND: The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans. Results from the phase 2a TUSCANY trial highlighted the safety and efficacy of PF-06480605 in ulcerative colitis. Preclinical and in vitro models have identified a role fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan-Zahraee, Mina, Ye, Zhan, Xi, Li, Baniecki, Mary Lynn, Li, Xingpeng, Hyde, Craig L, Zhang, Jenny, Raha, Nancy, Karlsson, Fridrik, Quan, Jie, Ziemek, Daniel, Neelakantan, Srividya, Lepsy, Christopher, Allegretti, Jessica R, Romatowski, Jacek, Scherl, Ellen J, Klopocka, Maria, Danese, Silvio, Chandra, Deepa E, Schoenbeck, Uwe, Vincent, Michael S, Longman, Randy, Hung, Kenneth E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic Science Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889296/
https://www.ncbi.nlm.nih.gov/pubmed/34427649
http://dx.doi.org/10.1093/ibd/izab193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889296/
https://www.ncbi.nlm.nih.gov/pubmed/34427649
http://dx.doi.org/10.1093/ibd/izab193

Ejemplares similares